CRISPR Therapeutics AG (CRSP): Total Liabilities
$343.43M
As of 2025-12-31
$904.22M
As of 2026-06-30
-2.2%
3-year compound annual growth
+16.0%
5-year compound annual growth
+10.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $343.43M | +10.8% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $309.95M | -10.6% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $346.77M | -5.7% | 2025-02-11, Balance as of period end |
| 2022-12-31 | $367.58M | +4.3% | 2024-02-21, Balance as of period end |
| 2021-12-31 | $352.42M | +115.2% | 2023-02-21, Balance as of period end |
| 2020-12-31 | $163.73M | +28.6% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $127.33M | +31.5% | 2021-02-16, Balance as of period end |
| 2018-12-31 | $96.82M | +15.9% | 2020-02-12, Balance as of period end |
| 2017-12-31 | $83.51M | -25.5% | 2019-02-25, Balance as of period end |
| 2016-12-31 | $112.12M | -9.6% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $124.03M | n/a | 2017-03-10, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $343.43M | +10.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $38.99M | +82.0% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $55.68M | +5.4% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $221.87M | +53.7% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $2.95M | -10.5% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $34.99M | -64.7% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
Compare CRSP, SRZN, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗